Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Prostate cancer in Denmark. Incidence, morbidity and mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Carcinoma of the prostate. Classification

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Carcinoma of the prostate. Early diagnosis--screening

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Carcinoma of the prostate. Prognostic factors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Evaluation of algorithm development approaches: Development of biomarker panels for early detection of colorectal lesions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prognostic factors for relapse in patients with clinical stage I testicular cancer: protocol for a Danish nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prognostic factors for relapse in patients with clinical stage I testicular cancer: protocol for a Danish nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Mandibular advancement device therapy for obstructive sleep apnea: a prospective study on predictors of treatment success

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
In 245 patients with previously untreated advanced carcinoma of the prostate, serum concentrations of testosterone have been measured before androgen deprivation therapy, and patients were divided in quartiles according to their serum concentration. Pretreatment level of serum testosterone was confirmed as having significant prognostic value on progression-free, overall, and cancer-specific survival, and the hazard ratios of lower quartiles compared to the upper quartile for these endpoints were 2.3, 2.1, and 2.0, respectively. However, correlations with symptomatology and other pretreatment parameters suggest that low serum testosterone merely is a consequence of the advanced malignancy rather than a causative factor in the pathogenesis of prostatic cancer.
OriginalsprogEngelsk
BogserieScandinavian Journal of Urology and Nephrology. Supplement
Vol/bind157
Sider (fra-til)41-7
Antal sider7
ISSN0300-8886
StatusUdgivet - 1994

ID: 36731248